Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study

Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study

Apixaban and rivaroxaban require lead-in dosing for 7 and 21 days, respectively, when treating venous thromboembolism (VTE). However, no evidence exists to support subtracting parenteral anticoagulation days from total lead-in dosing. A multicenter study was conducted, including adult patients with...

Full description

Bibliographic Details
Main Authors: Omar A. Alshaya, Ghazwa B. Korayem, Majed S. Al Yami, Asma H. Qudayr, Sara Althewaibi, Lolwa Fetyani, Shaden Alshehri, Fai Alnashmi, Maram Albasseet, Lina Alshehri, Lina M. Alhushan, Omar A. Almohammed
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Clinical Medicine
Subjects:
venous thromboembolism
bleeding
lead-in
oral anticoagulant
apixaban
rivaroxaban
Online Access:https://www.mdpi.com/2077-0383/12/1/199

Similar Items

Similar Items